Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10229782 | 0.83 | CYP1A2 (0.51) | CXCR4TRPA1CYP1A2CYP2D6HRH3 | |
| SCHEMBL5732523 | 0.80 | CXCR4 (0.40) | CXCR4TRPA1CYP1A2CYP2D6HRH3 | |
| SCHEMBL507751 | 0.80 | CXCR4 (0.40) | CXCR4TRPA1CYP1A2CYP2D6HRH3 | |
| SCHEMBL10223944 | 0.76 | ESR1 (0.45) | CYP1A2CYP2D6HRH3ESR1 | |
| SCHEMBL28819054 | 0.76 | NFE2L2 (0.44) | CXCR4TRPA1HRH3HTR3AHRH4 | |
| SCHEMBL21240974 | 0.76 | MAP4K4 (0.42) | TRPA1HRH3HTR3AHRH4CYP11B2 | |
| SCHEMBL21600605 | 0.74 | CXCR4 (0.44) | CXCR4TRPA1CYP1A2CYP2D6HRH3 | |
| SCHEMBL14588227 | 0.74 | HRH3 (0.49) | CXCR4CYP1A2CYP2D6HRH3 | |
| SCHEMBL506993 | 0.73 | L3MBTL1 (0.44) | — | |
| SCHEMBL18924323 | 0.73 | CYP1A2 (0.35) | CXCR4CYP1A2CYP2D6HRH3HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189826-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189826-B2 | Heterocyclic compounds and methods of use | HRAS, VHL, ESRRB | CXCR4 1405/4885TRPA1 4844/4885CYP1A2 1796/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | CXCR4 1405/4885TRPA1 4844/4885CYP1A2 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.